Showing results (301-310 of 321) with videos related to
Sort By:
Pageof 33
Diabetes, Obesity & Metabolism|December 20, 2014
Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extensionS-M Jin, S W Park, K-H Yoon, et al.Diabetes, Obesity & Metabolism|November 23, 2012
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetesS J Yang, K W Min, S K Gupta, et al.The Journal of Hospital Infection|July 19, 2019
Chlorhexidine sensitivity in staphylococci isolated from patients with central line-associated bloodstream infectionK I Jun, Y Choi, K Kwon, et al.Journal of Hepatology|April 17, 2022
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinomaSamuel Chuah, Joycelyn Lee, Yuan Song, et al.Cancer Letters|October 24, 2022
IFNγ-IL-17+ CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinomaYun Hua Lee, Samuel Chuah, Phuong H D Nguyen, et al.Nature Communications|September 19, 2019
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's diseaseXavier Hadoux, Flora Hui, Jeremiah K H Lim, et al.International Journal of Radiation Oncology, Biology, Physics|June 17, 2020
High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint BlockadeKevin L M Chua, Michael Fehlings, Eugenia L L Yeo, et al.Frontiers in Oncology|June 28, 2024
Transcriptomic convergence despite genomic divergence drive field cancerization in synchronous squamous tumorsQiu Xuan Tan, Nicholas B Shannon, Weng Khong Lim, et al.The Lancet. Gastroenterology & Hepatology|October 25, 2021
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trialDavid Tai, Kelvin Loke, Apoorva Gogna, et al.Nature Communications|January 12, 2021
Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinomaPhuong H D Nguyen, Siming Ma, Cheryl Z J Phua, et al.Pageof 33